News
Hims & Hers Health Shocks Investors With a Long-Term Forecast, but Is the Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
27m
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo ...
Hims & Hers, the telehealth and wellness company, has hired a veteran of the autonomous vehicle industry as its next chief ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback